The following is a summary of “Impaired Thyroid Hormone Sensitivity Increases Risk of Cardiovascular Events in Patients Undergoing Coronary Angiography,” published in the June 2024 issue of Endocrinology by Qin, et al.
For a study, researchers sought to explore how thyroid hormone sensitivity related to the risk of major adverse cardiovascular events (MACE) and cardiovascular death among individuals with normal thyroid function undergoing coronary angiography.
In a prospective cohort study, 1,470 euthyroid participants who underwent coronary angiography between March and November 2013 were enrolled. Follow-up was conducted from July to November 2022. To gauge thyroid hormone sensitivity, they calculated the thyrotroph thyroxine resistance index (TT4RI), TSH index (TSHI), and feedback quantile-based index (TFQI). Using Kaplan–Meier curves and multivariable Cox proportional hazard models, they analyzed the connection between thyroid hormone sensitivity and the risk of MACE and cardiovascular death.
Among the 1,089 participants who completed the follow-up, 342 experienced MACE, and 77 had cardiovascular deaths during a median follow-up duration of 111 months. After adjusting for various factors, the study found that elevated levels of TFQI (HR = 1.41; 95% CI, 1.08-1.84; P for trend = .01), TT4RI (HR = 1.40; 95% CI, 1.06-1.84; P for trend = .02), and TSHI (HR = 1.61; 95% CI, 1.22-2.13; P for trend = .001) were associated with an increased risk of MACE. Moreover, higher TFQI (HR = 2.21; 95% CI, 1.17-4.17; P for trend = .02) and TSHI (HR = 2.05; 95% CI, 1.08-3.91; P for trend = .03) levels were linked to a greater risk of cardiovascular death.
The findings suggested that impaired sensitivity to thyroid hormone is linked to heightened risks of MACE and cardiovascular death in euthyroid individuals undergoing coronary angiography.
Reference: academic.oup.com/jcem/article-abstract/109/6/1550/7476632